Abstract: A waterproof motor, which includes a stator arranged on a motor housing, a rotor arranged in the motor housing, a rotating shaft connected to the rotor and extending out of the motor housing, and a circuit board arranged in the motor housing. An inner end cap is arranged in the motor housing, between the rotor and the circuit board, which surround the rotating shaft and extends in the radial direction of the rotating shaft.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may transmit, to a base station, information indicating a Layer 1 signal to interference plus noise ratio (L1-SINR) measurement capability of the UE. In some aspects, the information indicating the L1-SINR measurement capability may include one or more individual configurations for one or more resources to carry a reference signal. The UE may receive, from the base station, a reference signal carried on the one or more resources based at least in part on the L1-SINR measurement capability. Numerous other aspects are provided.

Abstract: The display panel includes a plurality of light-emitting areas and a plurality of non-light-emitting areas, the plurality of light-emitting areas being space apart from each other by the plurality of non-light-emitting area; light-emitting elements each located in one of the plurality of light-emitting areas and including an anode and a cathode that are opposite to each other, and a light-emitting layer located therebetween; a cover layer covering a light-emission side of the light-emitting element. The cover layer includes a substrate and first dopants doped in the substrate, the first dopants are magnetic. When an external magnetic field intensity applied to the cover layer is changed by an amount greater than a preset magnetic field intensity, the first dopants in the substrate are rearranged from a first mode to a second mode.

Abstract: The present disclosure relates to compositions and methods for reducing side effects and/or enhancing cancer treatment that use modified immune cells expressing chimeric antigen receptors (CARs) or modified T cell receptors (TCRs). The modified immune cells, such as T cells or NK cells, can express CARs or TCRs targeting solid tumor antigens, white blood cell antigens like CD19, or bispecific CARs/TCRs targeting both. The methods include administering dasatinib to reduce the side effects associated with CAR T or TCR therapy and/or enhance cancer treatment. The modified cells can co-express additional therapeutic agents like cytokines.

Abstract: Certain aspects of the present disclosure provide techniques for determining an energy per resource element (EPRE) ratio for non-zero power (NZP) channel state information reference signals (CSI-RSs) when a device is measuring a wireless channel. A method that may be performed by a user equipment (UE) includes determining, based on an indication, an energy per resource element (EPRE) ratio for a non-zero power (NZP) channel state information reference signal (CSI-RS) resource; and measuring a channel based on the determined EPRE ratio and CSI-RS s associated with the NZP CSI-RS resource.

Abstract: A child crib includes a frame body, a corner component, a cloth component and a covering member. The cloth component at least partially covers the frame body. The corner component is connected to a handrail and a post of the frame body and exposed out of the cloth component. A first ring-shaped opening structure and a second ring-shaped opening structure are respectively formed by a first side and a second side of a covering body of the covering member. When the first side of the covering body is connected to a first side of the cloth component, by positioning the second side of the covering body on a second side of the cloth component, the first side and the second side of the cloth component are respectively enclosed by the first ring-shaped opening structure and the second ring-shaped opening structure, and the covering member covers the corner component.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive a configuration that indicates a channel state information reference signal (CSI-RS) Layer 3 (L3) signal corresponding to a first cell. The UE may select, based at least in part on an angle of arrival (AoA) difference between a first AoA and a second AoA, a UE reception (Rx) beam for receiving the CSI-RS L3 signal, wherein the first AoA is associated with the CSI-RS L3 signal, and wherein the second AoA is associated with a communication corresponding to a second cell. The UE may receive the CSI-RS L3 signal using the UE Rx beam. Numerous other aspects are provided.

Abstract: This disclosure provides systems, methods and apparatus for wireless communications. In one aspect, a device, such as a user equipment (UE) may receive a configuration including one or more channel state information (CSI) measurement resources associated with a set of CSI hypotheses. The set of CSI hypotheses may correspond to a set of transmission configuration indicator (TCI) states, or a CSI interference measurement (CSIIM) resource, or both. The UE may select a first CSI measurement resource of the one or more CSI measurement resources for a channel measurement based on a CSI hypothesis of the set of CSI hypotheses. The UE also may select the CSIIM resource or a second CSI measurement resource for an interference measurement based on the CSI hypothesis of the set of CSI hypotheses. The UE may, as a result, transmit a report based on the channel measurement or the interference measurement, or both.

Abstract: The present disclosure relates to compositions and methods for enhancing CAR T therapy through uses of co-stimulation. Some embodiments relate to an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) and an agent associated with a co-stimulatory molecule, the CAR comprising an intracellular domain of a costimulatory molecule.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment may determine that an enhanced type-II channel state information (CSI) report configuration, associated with transmitting CSI feedback to a base station, is to be overridden; and transmit, based at least in part on determining that the enhanced type-II CSI report configuration is to be overridden, a CSI report using another CSI report configuration, wherein the CSI report includes the CSI feedback and an indication that the enhanced type-II CSI report configuration has been overridden. Numerous other aspects are provided.

Abstract: A service deployment method determining an execution path of a to-be-deployed service, the execution path includes a first execution device and a second execution device; obtaining a first quality of service (QoS) of the first execution device; obtaining a second QoS of the second execution device; calculating a third QoS of the execution path based on the first QoS and the second QoS; obtaining a preset QoS of the to-be-deployed service; making a first determination that a first relationship between the third QoS and the preset QoS meets a preset rule; and deploying, in response to the first determination, the to-be-deployed service on the execution path.

Abstract: A method is implemented in a digital unit connected with a plurality of distributed antennas including a first antenna, a second antenna and a third antenna. The method comprises: causing transmitting a first signal from the first antenna, a second signal from the second antenna, and a third signal from the third antenna in a same frequency resource; obtaining a receiver and transmitter side loop-back phase difference between the first antenna and the second antenna based on the first signal received at the third antenna, the second signal received at the third antenna, the third signal received at the first antenna, and the third signal received at the second antenna; and obtaining estimations of a time delay difference and an initial phase difference between the first and second antennas based on the obtained loop-back phase difference.

Abstract: The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may determine one or more channel state information (CSI) reference signal (CSI-RS) capabilities associated with multiple transmit receive point (multi-TRP) CSI measurement, each CSI-RS capability indicating at least one of a number of active CSI-RS resources or a number of active CSI-RS ports supported by the UE for multi-TRP CSI measurement. The UE may transmit an indication of the one or more CSI-RS capabilities associated with multi-TRP CSI measurement. Numerous other aspects are provided.

Abstract: This disclosure provides systems, methods and apparatus for channel state information reference signal (CSI-RS) resource activation or deactivation within a resource set. In one aspect, a base station (BS) may transmit control signaling to a user equipment (UE) including an indication to switch an activity status of one or more CSI measurement resources within a CSI resource set from an activated state or a deactivated state to the other. The control signaling may include a bitmap indication for the activity status for the one or more CSI measurement resources or a CSI measurement resource identifier for each CSI measurement resource in an activated state. The UE may transmit a CSI report including information from measuring a channel state, a channel interference, or both for the one or more CSI measurement resources based on the activity status of each.

Abstract: Neural representations may be used for multi-view reconstruction of scenes. A plurality of color images representing a scene from a plurality of camera poses may be received. For each point of a plurality of points along a ray, a signed distance and a color value may be determined as a function of a feature volume, a first neural network, and a second neural network. A predicted output color may be determined as a function of the density. At least one of the first neural network, the second neural network, the feature volume, or the transformation parameter may be adjusted based on the predicted output color and a corresponding target color obtained based on one of the color images. A three-dimensional representation of the scene may be displayed based on at least one of the first neural network, the second neural network, the feature volume, or the transformation parameter.

Abstract: Embodiments relate to compositions and methods for treating solid tumors. For example, the compositions comprise modified cells comprising an isolated polynucleotide comprising a polynucleotide encoding a nuclear factor of activated T cells (NFAT) promoter operatively associated with a polynucleotide encoding FLT3L.

Abstract: The present disclosure relates to a fusion protein and uses thereof. For example, the fusion protein comprises an extra-cellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is derived from a first molecule, and the intracellular domain is derived from a second molecule. The first molecule is different from the second molecule, and the second molecule comprises OX40, CD40, 4-1 BB, GITR, ICOS, CD28, CD27, HER2, EGFR, EL-10R, IL-12R, IL-18R1, IL-23R, GP130, or IL-15Ra.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.